Clinical Biotechnology Articles
-
The Netflix of Digital Biology? Recursion Is Reimagining Drug Discovery
By applying a proprietary operating system to drug discovery, the Utah clinical-stage biotechnology company expects to turn drug discovery from sequential testing into a search problem. Unmet clinical needs often serve as the fundamental driving force behind drug discovery programs. During lead discovery, an intensive search ensues to find a drug-like small molecule or biological therapeutic, ...
By Recursion
-
The Spark for Decoding Biology: An Origin Story
Recursion is entering an exciting period in our evolution as a clinical-stage biotechnology company. We recently announced that we’ve enrolled the first patient in the first human efficacy trial in our company’s history — a significant milestone for us, and for the patients we hope to serve. Our Phase 2 trial is investigating the treatment of a disease called cerebral ...
By Recursion
-
Treos Bio Announces the Publication of Preclinical Data in Frontiers in Genetics Showing its COVID-19 Peptide Vaccine Mimics the Diversity of T Cell Immunity Produced by Natural SARS-CoV-2 Infection
LONDON, June 28, 2021 (GLOBE NEWSWIRE) – Treos Bio Limited (“Treos”), a clinical stage biotechnology company using data science and proprietary biomarkers to develop precision off-the-shelf and personalized peptide cancer immunotherapies, today announced the publication of a peer-reviewed article titled “A Peptide Vaccine Candidate Tailored to Individuals’ Genetics ...
-
UW–Madison, FluGen, Bharat Biotech to develop CoroFlu, a coronavirus vaccine
MADISON, Wis.–(BUSINESS WIRE)–An international collaboration of virologists at the University of Wisconsin–Madison and the vaccine companies FluGen and Bharat Biotech has begun the development and testing of a unique vaccine against COVID-19 called CoroFlu. UW–Madison, FluGen, Bharat Biotech to develop CoroFlu, a coronavirus vaccineTweet this CoroFlu will build on the ...
By FluGen, Inc.
-
Origin files patent application to protect its proposed treatment for viral and bacterial respiratory infections
Origin, Inc., a Phase III clinical stage biotechnology company, today announced that it has filed a provisional U.S. patent application to enhance the ability of its plasma-generated nitric oxide (NO) antimicrobial and antiviral therapy to be used to treat infections in the respiratory tract and other enclosed spaces in the body. The enhancements are designed to allow Origin’s NO therapy to ...
By Origin, Inc
-
Origin applies to China regulatory agency for clinical pathway classification
Origin, Inc., a Phase III clinical-stage biotechnology company, today announced that it had applied to NMPA (formerly CFDA) for classification of its plasma-generated nitric oxide device for the purposes of conducting clinical trials in Hong Kong and mainland China, and that NMPA had accepted its submission. A determination is expected within sixty business days. Origin is in preliminary ...
By Origin, Inc
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you